Arkansas PASSE Laboratory Testing Policies
The policies below are only effective for AR PASSE plans between 01/01/2022 through 05/08/2022.
F2019: Flow Cytometry - Effective Date: 01-01-2022
G2002: Cervical Cancer Screening - Effective Date: 01-01-2022
G2005: Vitamin D Testing - Effective Date: 01-01-2022
G2006: Hemoglobin A1c - Effective Date: 01-01-2022
G2007: Prostate Biopsies - Effective Date: 01-01-2022
G2008: Prostate Specific Antigen PSA Testing - Effective Date: 01-01-2022
G2009: Preventive Screening in Adults - Effective Date: 01-01-2022
G2011: Diagnostic Testing of Iron Homeostasis and Metabolism - Effective Date: 01-01-2022
G2013: Hormonal Testing in Adult Males - Effective Date: 01-01-2022
G2014: Vitamin B12 and Methylmalonic Acid Testing - Effective Date: 01-01-2022
G2022: ANA/ENA Testing - Effective Date: 01-01-2022
G2023: Pre Operative Testing - Effective Date: 01-01-2022 to 04-30-2022
G2031: Allergen Testing - Effective Date: 01-01-2022
G2035: Prenatal Screening - Effective Date: 01-01-2022
G2036: Hepatitis C - Effective Date: 01-01-2022
G2036: Hepatitis C - Effective Date: 07-01-2022
G2042: Pediatric Preventive Screening - Effective Date: 01-01-2022
G2043: Celiac Disease - Effective Date: 01-01-2022
G2044: Helicobacter pylori Testing - Effective Date: 01-01-2022
G2045: Thyroid Disease Testing - Effective Date: 01-01-2022
G2048: Biochemical Markers of Alzheimer Disease and Dementia - Effective Date: 01-01-2022
G2050: Cardiovascular Disease Risk Assessment - Effective Date: 01-01-2022
G2051: Bone Turnover Markers Testing - Effective Date: 01-01-2022
G2055: Prenatal Screening for Fetal Aneuploidy - Effective Date: 01-01-2022
G2056: Diagnosis of Idiopathic Environmental Intolerance - Effective Date: 01-01-2022
G2059: Epithelial Cell Cytology in Breast Cancer Risk Assessment - Effective Date: 01-01-2022
G2060: Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing - Effective Date: 01-01-2022
G2061: Fecal Calprotectin Testing - Effective Date: 01-01-2022
G2063: Testing for Diagnosis of Active or Latent Tuberculosis - Effective Date: 01-01-2022
G2098: Immune Cell Function Assay - Effective Date: 01-01-2022
G2099: Intracellular Micronutrient Analysis - Effective Date: 01-01-2022
G2100: In Vitro Chemoresistance and Chemosensitivity Assays - Effective Date: 01-01-2022
G2105: Immunopharmacologic Monitoring of Therapeutic Serum Antibodies - Effective Date: 01-01-2022
G2107: Measurement of Thromboxane Metabolites for ASA Resistance - Effective Date: 01-01-2022
G2110: Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease - Effective Date: 01-01-2022
G2113: Oral Screening Lesion Identification Systems and Genetic Screening - Effective Date: 01-01-2022
G2113: Oral Screening Lesion Identification Systems and Genetic Screening - Effective Date: 07-01-2022
G2115: Metabolite Markers of Thiopurines Testing - Effective Date: 01-01-2022
G2119: Diagnostic Testing of Influenza - Effective Date: 01-01-2022
G2120: Salivary Hormone Testing - Effective Date: 01-01-2022
G2121: Lab Testing for the Diagnosis of IBD - Effective Date: 01-01-2022
G2123: Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases - Effective Date: 01-01-2022
G2124: Serum Tumor Markers for Malignancies - Effective Date: 01-01-2022
G2125: Urinary Tumor Markers For Bladder Cancer - Effective Date: 01-01-2022
G2127: Vectra DA Blood Test for Rheumatoid Arthritis - Effective Date: 01-01-2022
G2130: ST2 Assay for Chronic Heart Failure - Effective Date: 01-01-2022
G2130: ST2 Assay for Chronic Heart Failure - Effective Date: 07-01-2022
G2132: Erectile Dysfunction - Effective Date: 01-01-2022
G2132: Erectile Dysfunction - Effective Date: 07-01-2022
G2133: ZIKA Virus Risk Assessment - Effective Date: 01-01-2022
G2138: Evaluation of Dry Eyes - Effective Date: 01-01-2022
G2143: Lyme Disease - Effective Date: 01-01-2022
G2149: Pathogen Panel Testing - Effective Date: 01-01-2022
G2150: Cardiac Biomarkers for Myocardial Infarction - Effective Date: 01-01-2022
G2150: Cardiac Biomarkers for Myocardial Infarction - Effective Date: 07-01-2022
G2153: Pancreatic Enzyme Testing for Acute Pancreatitis - Effective Date: 01-01-2022
G2153: Pancreatic Enzyme Testing for Acute Pancreatitis - Effective Date: 07-01-2022
G2154: Folate Testing - Effective Date: 01-01-2022
G2154: Folate Testing - Effective Date: 07-01-2022
G2155: General Inflammation Testing - Effective Date: 01-01-2022
G2155: General Inflammation Testing - Effective Date: 07-01-2022
G2156: Urine Culture Testing For Bacteria - Effective Date: 01-01-2022
G2156: Urine Culture Testing for Bacteria - Effective Date: 07-01-2022
G2157: Diagnostic Testing Of Common Sexually Transmitted Infections - Effective Date: 01-01-2022
G2158: Testing for Mosquito- or Tick-Related Infections - Effective Date: 01-01-2022
G2159: B Hemolytic Streptococcus Testing - Effective Date: 01-01-2022
G2161: Hormonal Testing of Adult Females - Effective Date: 01-01-2022
G2164: Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing - Effective Date: 01-01-2022
G2173: Gamma-glutamyl Transferase - Effective Date: 01-01-2022
G2173: Gamma-glutamyl Transferase - Effective Date: 07-01-2022
G2174: Coronavirus Testing in the Outpatient Setting - Effective Date: 01-01-2022
M2041: Venous and Arterial Thrombosis Risk Testing - Effective Date: 01-01-2022
M2057: Diagnosis of Vaginitis including Multi-target PCR Testing - Effective Date: 01-01-2022
M2058: Genetic Testing for Adolescent Idiopathic Scoliosis - Effective Date: 01-01-2022
M2058: Genetic Testing for Adolescent Idiopathic Scoliosis - Effective Date: 07-01-2022
M2068: Testing for Alpha-1 Antitrypsin Deficiency - Effective Date: 01-01-2022
M2068: Testing for Alpha-1 Antitrypsin Deficiency - Effective Date: 07-01-2022
M2093: HIV Genotyping and Phenotyping - Effective Date: 01-01-2022
M2093: HIV Genotyping and Phenotyping - Effective Date: 07-01-2022
M2097: Identification Of Microorganisms Using Nucleic Acid Probes - Effective Date: 01-01-2022
M2097: Identification of Microorganisms using Nucleic Acid Probes - Effective Date: 07-01-2022
M2112: Nerve Fiber Density Testing - Effective Date: 01-01-2022
M2116: Plasma HIV-1 and HIV-2 RNA Quantification for HIV Infection - Effective Date: 01-01-2022
M2136: DNA Ploidy Cell Cycle Analysis - Effective Date: 01-01-2022
M2136: DNA Ploidy Cell Cycle Analysis - Effective Date: 07-01-2022
M2141: Testing of Homocysteine Metabolism Related Conditions - Effective Date: 01-01-2022
M2172: Onychomycosis Testing - Effective Date: 01-01-2022
M2176: Testing for Autism Spectrum Disorder and Developmental Delay - Effective Date: 01-01-2022
P2018: Immunohistochemistry - Effective Date: 01-01-2022
R2162: Laboratory Procedures Reimbursement Policy - Effective Date: 07-01-2022
T2015: Prescription Medication and Illicit Drug Testing in the Outpatient Setting - Effective Date: 01-01-2022
